Skip to main content
. Author manuscript; available in PMC: 2015 Oct 15.
Published in final edited form as: Int J Cancer. 2014 Mar 20;135(8):1931–1939. doi: 10.1002/ijc.28838

Figure 1.

Figure 1

Additional cancer risk reduction and net monetary benefit (INMB) associated with targeted interventions to improve compliance to screening guidelines. The height of each bar corresponds to the y-axis (additional cancer risk reduction compared to status quo screening using cytology) for increasing compliance to100% within each scenario or for an incremental (2%) increase in screening adherence, designated by white lines. The INMBs associated with human papillomavirus (HPV)-based scenario are inclusive of the benefit (designated by the darkest solid box) and costs associated with switching current screeners to primary HPV testing for women age 30 years or older. For the primary HPV testing strategy, we assumed that women with a positive HPV test underwent additional cytology testing. Those who were both HPV and cytology-positive (i.e., atypical cells or worse) were referred directly to colposcopy; for women HPV-positive but cytology-negative, two additional persistent HPV-positive, cytology-negative results were required (each 12 months apart) prior to prompting referral to colposcopy.